MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting

ViewRay celebrates 10-years as the first and only company to offer real-time tissue tracking with automatic beam gating and will host a lunch symposium highlighting new MRIdian A3i features  

CLEVELAND, May 6, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with nearly 40 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 6-10, 2022 online and in-person in Copenhagen, Denmark.

MRIdian-focused presentations and posters, submitted by MRIdian clinical teams from across the globe and accepted as part of ESTRO's Scientific Sessions, highlight MRIdian's clinical value treating a wide variety of cancers including pancreatic, prostate, liver, rectal, cervical and central/ultracentral lung tumors. Additional topics highlighted include patient satisfaction, cost/benefit analysis, and single day MRIdian treatments.

On Friday, May 6 at 12:30 pm CEST GenesisCare will host a symposium titled, "An MR Guided Revolution," featuring MRIdian users from GenesisCare, Amsterdam UMC, Miami Cancer Institute, University Hospital Munich, Moffit Cancer Center and UCLA discussing innovations in MR-guided radiotherapy and its utility in lung, gastrointestinal and urological cancers. The event will be held both in-person at the Admiral Hotel in Copenhagen and live-streamed for virtual attendees. Registration available at bit.ly/3y98pZw.

MRIdian A3i* is ViewRay's 4th generation of real-time tissue tracking with automatic beam gating, now coupled with new treatment delivery capabilities focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility. ViewRay will host a lunch symposium on Saturday, May 7 from 1:00-2:00 pm CEST in Hall D1 titled, "MRIdian A3i* - ViewRay's Newest Innovations of MR Guided RT". The presentation, which will be given by Drs. Frank Lagerwaard, Miguel Palacios (Amsterdam UMC), and Drew Moghanaki (UCLA).

This symposium will highlight MRIdian A3i features including MRI imaging sequences, automated workflow steps, on-table auto-contouring tools, multiplanar tissue tracking and automated beam gating, as well as the capability for clinicians to work collaboratively during patient treatments. The symposium will also discuss ViewRay's new brain treatment package.

This month marks 10 years since ViewRay introduced real-time tissue tracking with automatic beam gating. To date, MRIdian customers have treated more than 21,000 patients utilizing this feature on over 200,000 fractions. MRIdian remains the first and only system to offer real-time tissue tracking with automatic beam gating. 

Visitors to ViewRay's booth #1050 can also see demonstrations and presentations of MRIdian A3i* and the new brain treatment package. They can also hear first-hand experience from clinicians around the world highlighting MRIdian's benefits treating a variety of cancers including:

Saturday, May 7

• MRIdian SMART for Lung Cancer: Dr. Stephen Rosenberg, Moffitt Cancer Center
• MRIdian SMART for Lattice treatment in Liver: Dr. Enis Özyar, Acibadem Maslak Hospital        

Sunday, May 8

• MRIdian SMART for Oligometastatic Cancer: Dr. Lauren Henke, Washington University
• MRIdian SMART for Heart: Dr. Luca Boldrini, Gemelli
• Synthetic CT with MRIdian Images: Dr. Davide Cusumano, Mater Olbia Hospital

Monday, May 9

• MRIdian Solutions for Pancreas Cancer: Dr. Michael Chuong, Miami Cancer Institute
• MRIdian SMART for Liver SABR: Dr. Agnès Tallet, Institut Paoli-Calmettes, Marseille
• MRIdian Solutions for Prostate Cancer: Dr. Philip Camilleri, GenesisCare Oxford

Over 21,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

* MRIdian A3i functions are only for sale in the US, and information herein regarding those functions are intended for demonstration purposes only and cannot be made available for sale until applicable regulations are met.

Disclaimer:
The opinions and clinical experiences discussed herein are specific to the featured physicians and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in this press release are not indicative of typical or future results.

Safety Statement
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, disruptions in the supply or changes in costs of raw materials, labor, product components or transportation services as a result of inflation, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

SOURCE ViewRay, Inc.